List of Excipients in Branded Drug PARLODEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Validus Pharmaceuticals LLC	PARLODEL	bromocriptine mesylate	30698-202	LACTOSE
Validus Pharmaceuticals LLC	PARLODEL	bromocriptine mesylate	30698-202	MAGNESIUM STEARATE
Validus Pharmaceuticals LLC	PARLODEL	bromocriptine mesylate	30698-202	MALEIC ACID
Validus Pharmaceuticals LLC	PARLODEL	bromocriptine mesylate	30698-202	POVIDONE

Parlodel Excipient Strategy and Commercial Opportunities for Bromocriptine Mesylate

Last updated: August 6, 2026

Parlodel is an established oral bromocriptine mesylate product with limited active-ingredient patent leverage and substantial opportunity in generic manufacturing, excipient optimization, supply reliability, and differentiated oral delivery. The strongest commercial strategies are low-cost immediate-release tablets, capsule line extensions, pediatric or dysphagia-friendly presentations, and formulation improvements that reduce nausea, improve dose flexibility, or simplify administration. New excipient-based products would need to overcome the commercial constraint of competing against mature generic bromocriptine products.

What drug and dosage forms does Parlodel contain?

Parlodel contains bromocriptine mesylate, an ergot-derived dopamine agonist. In the United States, the product has been marketed primarily as:

Product	Strength	Dosage form	Main regulatory role
Parlodel	2.5 mg	Immediate-release tablet	Hyperprolactinemia, acromegaly, Parkinson's disease and other labeled uses
Parlodel	5 mg	Capsule	Dose escalation and maintenance therapy
Cycloset	0.8 mg	Immediate-release tablet	Type 2 diabetes mellitus

The products are oral immediate-release formulations. Bromocriptine mesylate is used because the mesylate salt provides a practical solid form for oral dosage manufacturing. The drug has low daily dosing requirements in some indications but can require gradual titration because of nausea, vomiting, orthostatic hypotension, dizziness and other dopaminergic adverse effects.[1][2]

Parlodel and Cycloset are distinct FDA products even though both contain bromocriptine mesylate. Their dosage strengths, labeling, titration schedules and therapeutic positioning differ.

What excipients are used in Parlodel tablets and capsules?

The exact excipient profile should be taken from the current FDA-approved labeling and the applicable reference listed drug record before a development or litigation decision. Public labeling identifies conventional oral solid-dose excipients for Parlodel, including tablet fillers, disintegrants, lubricants and capsule-shell materials.[1]

The functional excipient architecture is likely to include:

Excipient function	Commercial purpose	Development considerations
Diluent or filler	Controls tablet weight and improves content uniformity	Lactose, microcrystalline cellulose or other diluents may be evaluated
Disintegrant	Promotes breakup after oral administration	Sodium starch glycolate, crospovidone and croscarmellose sodium are common options
Lubricant	Prevents sticking and supports tablet ejection	Magnesium stearate concentration can affect dissolution
Glidant	Improves powder flow	Colloidal silicon dioxide can reduce blend variability
Capsule shell	Enables the 5 mg presentation	Gelatin or a vegetarian polymer may support a line extension
Colorant or opacifier	Supports product identification and light protection	Titanium dioxide or iron oxides may be used where permitted

For a generic Parlodel product, the objective is not to copy every excipient mechanically. The formulation must deliver pharmaceutical equivalence, acceptable dissolution, content uniformity, stability and bioequivalence. A Q1/Q2 match to the reference product can reduce regulatory risk, but it may constrain cost, supplier flexibility and excipient substitution.

Excipient selection also matters because bromocriptine products are frequently titrated. A formulation that produces variable disintegration or dissolution can create avoidable exposure variability during dose escalation.

What excipient strategy is most commercially attractive for bromocriptine?

The most defensible strategy is a staged platform rather than a single novel formulation.

Low-cost generic immediate-release tablet

A 2.5 mg tablet remains the core opportunity. The target profile should include:

• robust content uniformity at low drug loading;
• rapid and reproducible disintegration;
• dissolution comparable with the reference product;
• low tablet weight;
• strong resistance to chipping during packaging and transport;
• compatibility with high-speed compression;
• low sensitivity to humidity;
• an excipient supply chain with at least two qualified sources.

Bromocriptine mesylate products may involve relatively low active loadings, particularly in the 2.5 mg tablet. Blend segregation and assay variation therefore require close control. Ordered excipients, granulation or validated direct-compression processing may be preferable to a formulation that depends on a narrow particle-size distribution.

Lactose-free or low-lactose formulation

A lactose-free product could address patients with lactose intolerance, although the commercial value is likely to be incremental because lactose intolerance does not automatically preclude the use of lactose-containing medicines. The stronger business case is manufacturing flexibility, allergen-positioning and access to markets where lactose-free labeling is commercially useful.

Microcrystalline cellulose, mannitol, dibasic calcium phosphate or starch-based systems could replace lactose, but each creates tradeoffs involving compactability, dissolution, hygroscopicity, tablet size and cost.

Capsule-to-tablet or tablet-to-capsule line extension

The 5 mg capsule creates an opportunity for a capsule-based generic with improved swallowability, altered visual identification or a vegetarian shell. A capsule may also support rapid development if powder filling is easier than compression at the target strength.

The main limitations are capsule-shell moisture sensitivity, fill-weight control and the need to establish stability under the intended packaging conditions. A capsule line extension is more commercially credible as a lifecycle or patient-preference product than as a high-value exclusivity strategy.

Orally disintegrating or multiparticulate product

An orally disintegrating tablet, mini-tablet or multiparticulate product could target patients with dysphagia, Parkinson's disease or difficulty swallowing conventional tablets. The formulation would need to control:

• bitter or unpleasant taste;
• rapid oral disintegration;
• dose uniformity;
• moisture uptake;
• friability;
• acceptable mouthfeel;
• dose flexibility during titration.

Taste masking may require polymer coating, ion exchange, complexation or a coated multiparticulate approach. These technologies add process steps and may create a larger regulatory burden than a conventional immediate-release generic.

Modified-release bromocriptine

A modified-release product could seek lower peak concentrations, reduced nausea or once-daily administration. The commercial rationale is stronger where adherence or tolerability limits treatment. The development risk is also materially higher because the sponsor would need to establish a new exposure profile and clinical relevance rather than rely solely on conventional immediate-release bioequivalence.

A modified-release product should not be treated as a simple excipient substitution. It could require a 505(b)(2) pathway or another application strategy depending on the product design and reference product relationship.

What FDA regulatory pathway applies to Parlodel generics?

A conventional generic bromocriptine product would generally be developed through an abbreviated new drug application, subject to the applicable FDA product-specific guidance and Orange Book reference listed drug requirements.[3][4]

The principal development routes are:

Product concept	Likely pathway	Key evidence
2.5 mg immediate-release tablet	ANDA	Pharmaceutical equivalence, bioequivalence, CMC and labeling
5 mg capsule equivalent	ANDA if an applicable RLD and dosage-form requirements are met	Bioequivalence and dosage-form equivalence
Different excipient composition	ANDA if the formulation remains within generic requirements	Comparative dissolution, bioequivalence and justification of differences
Orally disintegrating tablet	ANDA or 505(b)(2), depending on reference and design	Product-specific bioequivalence, in vitro performance and CMC
Modified-release product	Usually 505(b)(2) or a new drug application strategy	Exposure characterization and clinical or pharmacokinetic bridging
New indication or new dosing regimen	505(b)(2) or supplemental strategy	Clinical evidence and regulatory exclusivity analysis

Excipient differences may be acceptable in an ANDA, but they cannot create a clinically meaningful difference in safety, efficacy, labeling or performance. Inactive ingredients also require attention to FDA maximum potency limits, route-specific safety and labeling requirements.[5]

What is the Orange Book and patent status of Parlodel?

Parlodel is an old product. Its original composition, use and basic oral formulation patents are expected to have expired. The commercial issue is therefore generic competition, not protection from a strong active-ingredient patent estate.

The Orange Book remains the controlling source for current reference listed drug status, approved products, patents and regulatory exclusivities. Patent listings can change, and the status of individual entries must be checked against the current FDA database before filing an ANDA or assessing Paragraph IV exposure.[3]

For an old bromocriptine product, a practical patent review should examine:

1. the current Parlodel and bromocriptine mesylate Orange Book records;
2. any listed formulation or method-of-use patents;
3. unlisted formulation patents held by third parties;
4. patents covering taste masking, modified release, orally disintegrating systems or manufacturing processes;
5. pediatric exclusivity or other regulatory exclusivities;
6. Paragraph IV certifications and any associated litigation.

A generic sponsor should not assume that the absence of a major composition-of-matter patent eliminates all litigation risk. The residual risk is more likely to arise from formulation, method-of-use, polymorph, process or product-by-process claims than from bromocriptine itself.

When does Parlodel lose exclusivity and what does generic entry look like?

Parlodel's core small-molecule exclusivity expired decades ago. The product therefore has no apparent modern exclusivity barrier comparable with a newly approved small molecule or biologic. Generic entry is commercially feasible, subject to current Orange Book requirements and any enforceable listed patent.

The likely launch scenarios are:

Scenario	Commercial result
Multiple ANDA approvals	Rapid price erosion and distributor-driven competition
One or two reliable suppliers	Moderate price pressure with supply-premium opportunities
Shortage or manufacturing disruption	Temporary price increases and contract-manufacturing opportunities
Differentiated dosage form	Limited premium if the product solves swallowing, titration or tolerability problems
505(b)(2) reformulation	Potentially higher margin but greater clinical and regulatory investment

Bromocriptine demand is fragmented across hyperprolactinemia, acromegaly, Parkinson's disease and type 2 diabetes. Cabergoline and other dopamine agonists affect the commercial opportunity in hyperprolactinemia, while other Parkinson's therapies compete in neurologic use. Cycloset also competes with a broad diabetes market that includes metformin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors and insulin products.

Which companies are challenging Parlodel commercially?

The competitive field includes generic manufacturers and distributors rather than a single dominant challenger. Bromocriptine mesylate tablets and capsules have been marketed by multiple generic suppliers over time, including companies operating through abbreviated-application and contract-manufacturing models.

The key competitive variables are:

• FDA approval status;
• current commercial availability;
• 2.5 mg tablet and 5 mg capsule coverage;
• manufacturing-site reliability;
• ability to supply both bottles and institutional packaging;
• quality history;
• wholesale acquisition cost and net pricing;
• backorder and shortage performance;
• authorized-generic or brand-supply arrangements.

A company evaluating entry should use current FDA application and drug-shortage databases rather than historical supplier lists. Historical approval does not establish current commercial supply.

What licensing deals and partnership opportunities exist?

Publicly visible value is more likely to arise from supply and formulation partnerships than from licensing the bromocriptine molecule. Potential structures include:

Contract manufacturing

A manufacturer could supply bromocriptine tablets or capsules to a distributor, specialty-pharmacy platform or regional generic company. The value proposition is dependable supply, validated process capability and low minimum order quantities.

Formulation licensing

A differentiated ODT, multiparticulate or modified-release product could be licensed to a company with an established ANDA or 505(b)(2) commercialization platform. The license would be more defensible if supported by formulation patents and human pharmacokinetic data.

Regional commercialization

Bromocriptine products are marketed under different brand and generic names across jurisdictions. Regional partners may create value where the sponsor lacks local registration, pharmacovigilance infrastructure or distribution access. Patent and regulatory review must be performed country by country because approval status and market exclusivity differ.

Private-label supply

Private-label or co-branded supply can work for mature products when the buyer values continuity, packaging flexibility and dependable service more than molecule-level differentiation.

No major current licensing transaction should be assumed without a verified company announcement, securities filing or contract disclosure.

How strong is the patent estate for a new bromocriptine excipient formulation?

A new excipient formulation could obtain patent protection if it produces a non-obvious technical result and satisfies utility, written-description and enablement requirements. The strongest claims would usually combine:

• bromocriptine mesylate particle-size or solid-form parameters;
• a defined excipient ratio;
• a manufacturing process;
• dissolution limits;
• stability performance;
• reduced impurity formation;
• improved bioavailability or tolerability;
• a specific dosage form or release profile.

A patent limited to substituting one routine diluent for another would likely have weaker commercial durability. Claims supported by comparative data showing improved dissolution, lower variability, improved stability or reduced adverse effects have greater value.

The patent estate should be designed around multiple layers:

1. composition claims;
2. process claims;
3. dosage-form claims;
4. packaging and moisture-control claims;
5. method-of-use claims;
6. jurisdiction-specific applications.

The United States, European Union, Japan, China, India, Brazil and Canada should be assessed separately. A U.S. formulation patent does not create equivalent protection elsewhere.

What generic entry risks exist for an excipient-based Parlodel product?

The principal risks are commercial and regulatory:

• rapid price erosion after ANDA approval;
• limited annual demand;
• physician preference for cabergoline or other therapies;
• poor tolerability and titration-related discontinuation;
• formulation changes that alter dissolution;
• excipient supply disruption;
• inability to secure a profitable wholesale price;
• method-of-use patent disputes;
• shortage-driven demand that disappears after competitors return;
• a 505(b)(2) clinical program that cannot support premium pricing.

An excipient strategy should therefore be tied to a measurable customer problem. Lower cost, improved stability, easier swallowing, lower tablet burden or better dose titration are more credible commercial objectives than novelty alone.

What revenue exposure and commercial opportunity does Parlodel offer?

Brand Parlodel revenue is difficult to assess from public filings because bromocriptine products are mature, fragmented and often reported within broader generic or established-products portfolios. Publicly disclosed revenue should not be inferred from prescription volume without current market data.

The opportunity is better segmented by product type:

Opportunity	Margin potential	Investment level	Strategic assessment
Conventional 2.5 mg generic tablet	Low	Low to moderate	Volume and supply reliability play
5 mg capsule	Low to moderate	Low to moderate	Useful line extension
Lactose-free tablet	Moderate	Moderate	Limited differentiation unless customer demand is documented
ODT or dysphagia product	Moderate to high	Moderate to high	Potential lifecycle opportunity
Modified-release product	High if successful	High	Requires meaningful PK and clinical differentiation
Regional supply partnership	Moderate	Low to moderate	Attractive where supply is constrained
Specialty packaging and titration kit	Moderate	Low	Supports adherence and patient convenience

Key Takeaways

• Parlodel contains bromocriptine mesylate and is an established immediate-release oral product.
• Core molecule and original product exclusivity are expired; generic competition is the main market reality.
• The most practical entry is a 2.5 mg immediate-release tablet with strong content uniformity, dissolution and supply economics.
• A 5 mg capsule, lactose-free tablet, ODT or multiparticulate product could provide limited differentiation.
• Modified-release bromocriptine has greater upside but would likely require a higher-risk regulatory pathway.
• Current Orange Book listings, FDA application status and any Paragraph IV activity must be checked before a filing or freedom-to-operate decision.
• Formulation patents need comparative technical data. Routine excipient substitution alone is unlikely to create a strong moat.
• Commercial value is more likely to come from reliable supply, contract manufacturing and patient-centered dosage forms than from the legacy Parlodel brand.

FAQs

Is bromocriptine mesylate the same active ingredient as Parlodel?

Yes. Parlodel is a branded product containing bromocriptine mesylate. Generic products may use the same salt while differing in inactive ingredients, appearance, packaging and manufacturer.

Can a lactose-free bromocriptine tablet be filed as an ANDA?

Potentially. The product must satisfy the applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, dissolution, labeling and inactive-ingredient safety. A different excipient system does not automatically require a 505(b)(2) application.

Does an orally disintegrating bromocriptine product qualify for new patent protection?

It may, if the formulation and performance characteristics are novel and non-obvious. The patent value depends on claim scope, supporting data, enforceability and whether competitors can design around the formulation.

Is bromocriptine a strong candidate for a biosimilar strategy?

No. Bromocriptine is a synthetic small molecule, not a biologic. The relevant U.S. pathway is generally an ANDA or, for a materially differentiated product, a 505(b)(2) application.

Which bromocriptine formulation has the best commercial opportunity?

A conventional 2.5 mg tablet has the lowest regulatory and manufacturing risk. An ODT or modified-release product has greater differentiation potential but requires stronger clinical, pharmacokinetic and patent support.

References

1. U.S. Food and Drug Administration. (n.d.). Parlodel (bromocriptine mesylate) prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Cycloset (bromocriptine mesylate) prescribing information. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.
5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.